NCT04194242View on ClinicalTrials.gov

The Tolerability , Pharmacokinetics and Pharmacodynamics Study of HEC96719 Tablets in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

January 3, 2020

Primary Completion Date

July 17, 2020

Study Completion Date

July 17, 2020

Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
DRUG

HEC96719 tablets

0.1、0.2、0.5、1、2、3、4 mg HEC96719 tablet in day1

DRUG

Placebo tablet

0.1、0.2、0.5、1、2、3、4 mg Placebo tablet in day1

Trial Locations (1)

Unknown

The Shanghai xuhui district central hospital, Shanghai

All Listed Sponsors
lead

Sunshine Lake Pharma Co., Ltd.

INDUSTRY

NCT04194242 - The Tolerability , Pharmacokinetics and Pharmacodynamics Study of HEC96719 Tablets in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter